SOURCE: Gilead Sciences
DESCRIPTION:
As COVID-19 began to spread around the world, Gilead employees worked around the clock to advance the company’s investigational antiviral.
In the next episode of our “Possible” series, meet Laura Bauer, a scientist in the company’s Formulation and Process Development group. Learn how she worked with her team, colleagues at Gilead, and partners across a wide manufacturing and supply chain network to expand production.
Watch other episodes of our “Possible” series here.
KEYWORDS: NYSE:GILD, Gilead, COVID-19, antiviral
